Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Capecitabine in Low Risk Triple Negative Breast Cancer
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 198
- Registration Number
- NCT06787339
- Locations
- 🇨🇳
breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
Recruiting
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT06786169
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Precision Palliative Care for Patients with Advanced Esophageal Cancer
- Conditions
- Esophageal Cancer
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 624
- Registration Number
- NCT06787313
- Locations
- 🇨🇳
Fudan University, Shanghai, Shanghai, China
ORIENT-31 Regimen in Combination with SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Phase 2
Not yet recruiting
- Conditions
- NSCLC (advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- Interventions
- Drug: ORIENT-31 regimenRadiation: SBRT
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 53
- Registration Number
- NCT06775743
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: Irinotecan liposomes combined with cetuximab + vermofenib
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06763029
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study Protocol
Not Applicable
Active, not recruiting
- Conditions
- Musculoskeletal SymptomsBreast CancerEndocrine TherapyAromatase Inhibitors
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 24
- Registration Number
- NCT06754293
- Locations
- 🇨🇳
Shanghai Cancer Center, ShangHai, XuHui, China
Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Gastric (Stomach) Cancer
- Interventions
- Drug: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 141
- Registration Number
- NCT06748508
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Recruiting
- Conditions
- Metastatic Colorectal CancerBRAF V600 Mutation
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06749015
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Lymph Node Pathologic Grading Strategy
Recruiting
- Conditions
- Lung Adenocarcinoma
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2998
- Registration Number
- NCT06745830
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
POLA-R-CHP in the First-line Treatment of Transformed DLBCL
Phase 2
Recruiting
- Conditions
- Transformed Lymphoma
- Interventions
- Drug: POLA-R-CHP
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06743945
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China